CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Curatis Holding AG is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Curatis Holding AG
Weierweg 7
Phone: +41 619278777p:+41 619278777 LIESTAL, 4057  Switzerland Ticker: CURNCURN
Filed for Bankruptcy on 9/25/2023
On 9/25/2023, Kinarus Therapeutics Holding AG announced its decision to file for Bankruptcy with the Competent Courts in Basel.
Business Summary
Curatis Holding AG formerly Kinarus Therapeutics Holding AG is a Switzerland-based company that operates in specialty pharmaceutical and therapeutic drug industry. The Company conducts its work within clinical-stage area and focuses on the acquisition, development and commercialisation of medicines for the prevention, diagnosis and treatment of diseases. This is done by distributing specialty pharmaceuticals throughout Switzerland, with aims to expanded to larger European markets such as Germany, France, United Kingdom as well as Italy. The drugs and treatments produced are primarily developed in order to treat rare diseases, often referred to as orphan diseases, which receive little funding, relative to more common disorders.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board MarianBorovsky 47 3/1/2024 3/1/2024
Chief Executive Officer, Director RolandRutschmann 3/1/2024 3/1/2024
Interim Chief Financial Officer SubhasisRoy 12/1/2023 6/2/2022
5 additional Officers and Directors records available in full report.

Business Names
Business Name
4M Technologies
4M Technologies Holding
CURN
KNRS
PRFN

General Information
Number of Employees: 15 (As of 12/31/2013)
Outstanding Shares: 4,810,544 (As of 10/30/2024)
Shareholders: 491
Stock Exchange: SWF
Fax Number: +41 619278775


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, November 14, 2024